Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 15, 2003, Pages 40-46

  Kuebler, J Philip ^b   De Gramont, Aimery ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; INTERFERON; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; PLATINUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOXICITY; TREATMENT OUTCOME;

EID: 0141959171     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00404-4     Document Type: Conference Paper

References (30)

1. Jemal A, Murray T, Samuels A, et al: Cancer Statistics, 2003. CA Cancer J Clin 53:5-26, 2003
2. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 49:33-64, 1999
3. Lokich J, Bothe A, Fine N, et al: Phase I study of protracted venous infusion of 5-fluorouracil.Cancer 48:2565-2568, 1981
4. Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998
5. de Gramont A, Krulik M, Cady J, et al: High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 24:1499-1503, 1988
6. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997
7. Andre T, Colin P, Louvet C, et al: Phase III trial (GER-COR C96.1) comparing bimonthly LV5FU2 to monthly 5FU-leucovorin high dose (LV hd) in patients with Dukes B2 and C colon cancer. Proc Am Soc Clin Oncol 21:133a, 2002 (abstr 529)
8. Pitot HC, Wender DB, O'Connell MJ, et al: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15:2910-2919, 1997
9. Rougier P, Bugat R, Douillard JY, et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251-260, 1997
10. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998
11. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000
12. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000 (Erratum in Lancet 335:1372, 2000)
13. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000 (Erratum in Lancet 335:1372, 2000)
14. Raymond E, Faivre S, Woynarowski JM, et al: Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 25:4-12, 1998
15. Cvitkovic E, Bekradda M: Oxaliplatin: A new therapeutic option in colorectal cancer. Semin Oncol 26:647-662, 1999
16. André T, Louvet C, Raymond E, et al: Bimonthly highdose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 9:1251-1253, 1998
17. de Gramont A, Vignoud J, Tournigand C, et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33:214-219, 1997
18. André T, Bensmaine MA, Louvet C, et al: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17:3560-3568, 1999
19. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
20. Goldberg RM, Morton RF, Sargent DJ, et al: N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initia[toxicity and response data from a Gl Intergroup study. Proc Am Soc Clin Oncol 21:128a, 2002 (abstr 511)
21. de Gramont A, Boni C, Navarro M, et al: Oxaliplatin/5-FU/LV in adjuvant colon cancer: Safety results of the international randomized MOSAIC trial. Proc Am Soc Clin Oncol 21:132a, 2002 (abstr 525)
22. Rothenberg ML, Meropol NJ, Poplin EA, et al: Mortality, associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001
23. Tournigand C, Louvet C, Quinaux E, et al: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 20:124a, 2001 (abstr 494)
24. Maindrault-Goebel F, de Gramont A, Louvet C, et al: High-dose intensity oxaliplatin added to the simplified bi-monthly leucovorin and 5-fluorouacil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX7). Eur J Cancer 37:1000-1005, 2001
25. Maindrault-Goebel F, Louvet C, André T, et al: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 35:1338-1342, 1999
26. Artru P, Taieb J, Tournigand C, et al: FOLFOX7 / FOLFIRI (MIROX) regimen as (neo)adjuvant chemotherapy for patients with resectable metastatic colorectal cancer: Preliminary results. Proc Am Soc Clin Oncol 21:169a, 2002 (abstr 672)
27. Maindrault-Goebel F, Louvet C, Carola E, et al: Oxaliplatin reintroduction in patients pretreated with leucovorin (LV), 5-FU and oxaliplatin for metastatic colorectal cancer. A Gercor study. Proc Am Soc Clin Oncol 19:255a, 2000 (abstr 990)
28. Maindrault-Goebel F, de Gramont A, Louvet C, et al: Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 11:1477-1483, 2000
29. Maindrault F, Louvet C, Tournigand C, et al: Leucovorin, 5-fluorouracil infusion and irinotecan (FOLFIRI-3) in pretreated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 21:165a, 2002 (abstr 658)
30. Gervais H, Artru P, Louvet C, et al: Reintroduction of irinotecan in pretreated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 21:173a, 2002 (abstr 688)